Wall Street analysts expect Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Rating) to post ($0.49) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Verrica Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.36). Verrica Pharmaceuticals reported earnings per share of ($0.35) during the same quarter last year, which suggests a negative year over year growth rate of 40%. The firm is scheduled to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Verrica Pharmaceuticals will report full-year earnings of ($2.04) per share for the current fiscal year, with EPS estimates ranging from ($2.28) to ($1.79). For the next financial year, analysts anticipate that the business will post earnings of ($1.52) per share, with EPS estimates ranging from ($2.26) to ($1.05). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Verrica Pharmaceuticals.
Verrica Pharmaceuticals (NASDAQ:VRCA – Get Rating) last announced its quarterly earnings results on Wednesday, March 2nd. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.13.
Several hedge funds have recently modified their holdings of VRCA. BlackRock Inc. boosted its stake in shares of Verrica Pharmaceuticals by 23.1% in the fourth quarter. BlackRock Inc. now owns 794,466 shares of the company’s stock valued at $7,278,000 after buying an additional 149,248 shares during the period. Morgan Stanley raised its position in Verrica Pharmaceuticals by 2,540.4% during the second quarter. Morgan Stanley now owns 122,065 shares of the company’s stock valued at $1,380,000 after purchasing an additional 117,442 shares in the last quarter. Millennium Management LLC raised its position in Verrica Pharmaceuticals by 466.6% during the fourth quarter. Millennium Management LLC now owns 94,220 shares of the company’s stock valued at $863,000 after purchasing an additional 77,590 shares in the last quarter. Geode Capital Management LLC raised its position in Verrica Pharmaceuticals by 11.8% during the third quarter. Geode Capital Management LLC now owns 238,069 shares of the company’s stock valued at $2,975,000 after purchasing an additional 25,089 shares in the last quarter. Finally, Bank of America Corp DE raised its position in Verrica Pharmaceuticals by 182.9% during the fourth quarter. Bank of America Corp DE now owns 28,451 shares of the company’s stock valued at $260,000 after purchasing an additional 18,393 shares in the last quarter. Institutional investors and hedge funds own 34.58% of the company’s stock.
Shares of NASDAQ VRCA opened at $5.94 on Monday. The business’s 50 day moving average price is $7.42 and its two-hundred day moving average price is $8.59. The company has a market cap of $163.46 million, a PE ratio of -3.81 and a beta of 1.96. Verrica Pharmaceuticals has a twelve month low of $5.20 and a twelve month high of $14.79.
Verrica Pharmaceuticals Company Profile (Get Rating)
Verrica Pharmaceuticals Inc, a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.
- Get a free copy of the StockNews.com research report on Verrica Pharmaceuticals (VRCA)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.